Literature DB >> 3982223

Dihydroergotoxine decreases blood pressure in spontaneously hypertensive rats by interacting with peripheral dopamine receptors.

M Memo, G Sagheddu, M O Carruba, P Spano.   

Abstract

Dihydroergotoxine (10 micrograms/kg s.c.) decreased mean carotid blood pressure in urethane-anaesthetized spontaneously hypertensive rats but failed to modify the same parameter in normotensive rats. The effect was statistically significant 20 min after the injection and relatively long lasting (up to 90 min). Pharmacological characterization of the phenomenon indicated that it is mediated by stimulation of dopamine receptors, since pretreatment with haloperidol, cis-flupentixol but not with trans-flupentixol, completely prevent the reduction in blood pressure induced by dihydroergotoxine. Moreover, a challenge dose of dihydroergotoxine did not reduce mean blood pressure values in spontaneously hypertensive rats pretreated with domperidone or (-)sulpiride, but not with (+)sulpiride. These results suggest that the ergot derivative modifies the cardiovascular system by interaction with peripheral dopamine receptors of the DA2 type.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3982223     DOI: 10.1016/0024-3205(85)90375-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

1.  Reversal by the selective D-2 dopamine receptor blocker sulpiride of the hypotensive effect of co-dergocrine in elderly hypertensives.

Authors:  C Lombardi; R De Cotiis; C Spedini; C Missale; M Memo; P F Spano
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Hypotensive and bradycardic effects of talipexole (B-HT 920) in anaesthetized rabbits are antagonized by metoclopramide but not by yohimbine.

Authors:  R Palluk; J C Schilling; K Stockhaus; H Peil
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

3.  Cardiovascular regulation and lipoprotein profile during administration of co-dergocrine in essential hypertension.

Authors:  D E Uehlinger; P Weidmann; M P Gnaedinger
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects.

Authors:  P Dominiak; J Grevel; E Abisch; H Grobecker; H J Dennler; D Welzel
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Inhibition of the aldosterone response to sodium depletion in man by stimulation of dopamine DA2 receptors.

Authors:  C Lombardi; C Missale; R De Cotiis; C Spedini; G Pizzoccolo; M Memo; A Albertini; P F Spano
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.